Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Abeona Therapeutics Inc.

Market Cap 315M 272M 251M 235M 440M 29.96B 447M 2.96B 1.15B 14.58B 1.18B 1.16B 50.49B P/E Ratio 2026 *
-7.49x
P/E Ratio 2027 * -79x
Enterprise Value 315M 272M 251M 235M 440M 29.96B 447M 2.96B 1.15B 14.58B 1.18B 1.16B 50.49B EV / Sales 2026 *
4.81x
EV / Sales 2027 * 2.34x
Free-Float
79.31%
Yield 2026 *
-
Yield 2027 * -
09:05am Abeona Therapeutics Inc. Announces Resignation of Michael Amoroso as Member of Board of Directors, Nominating and Corporate Governance Committee, Effective June 11, 2026 CI
Jun. 04 Abeona Therapeutics Inc Participates in Pre-Investigational New Drug Meeting with Fda Regarding Abo-701 CI
May. 13 Abeona Therapeutics Inc., Q1 2026 Earnings Call, May 13, 2026
May. 13 Abeona Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
May. 11 Abeona Therapeutics Inc Activates Children's Hospital of Philadelphia as New Qualified Treatment Center for Zevaskyn CI
May. 11 Abeona Therapeutics announces activation of Children's Hospital of Philadelphia as a new qualified treatment center for Zevaskyn RE
Apr. 07 Abeona Therapeutics Inc. Appoints Keith A. Goldan as A New Independent Member to Its Board of Directors as Chairman of Audit Committee , Effective as of April 1, 2026 CI
Apr. 02 Ultragenyx Pharmaceutical Inc Announces U.S. FDA Acceptance of BLA Resubmission for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A CI
Apr. 02 Abeona Therapeutics Inc. Expands Patient Access to ZEVASKYN with Activation of New Qualified Treatment Center in New York CI
Mar. 17 Abeona Therapeutics Inc., Q4 2025 Earnings Call, Mar 17, 2026
Mar. 17 Abeona Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
Mar. 17 Abeona Therapeutics FY income from operations USD -89.448 million versus Ibes estimate USD -78.4 million RE
Mar. 09 Abeona Therapeutics Inc. Provides Update On Zevaskyn Commercial Launch CI
1 day+0.36%
1 week+1.74%
Current month-3.89%
1 month-2.20%
3 months+12.11%
6 months+3.64%
Current year+5.41%
1 week 5.24
Extreme 5.24
5.7
1 month 5.08
Extreme 5.08
5.94
Current year 4.23
Extreme 4.23
6.07
1 year 4
Extreme 4
7.54
3 years 2.83
Extreme 2.83
9.01
5 years 2.19
Extreme 2.19
45.91
10 years 2.19
Extreme 2.19
568.75
Manager TitleAgeSince
Chief Executive Officer 50 2021-10-14
Director of Finance/CFO 42 2022-03-13
Chief Tech/Sci/R&D Officer - 2025-10-19
Director TitleAgeSince
Chairman 48 2021-10-13
Director/Board Member 58 2006-02-28
Director/Board Member 65 2021-03-24
Date Insider Type Main position Quantity % Market Cap.
Jun. 08Sell

Executive/Senior Manager

-5,450 0.0096%
Jun. 08Sell

General Counsel

-6,305 0.0111%
Jun. 08Sell

Chief Financial Officer

-39,067 0.0685%
Change 5-day change 1-year change 3-year change Capi.($)
+0.36%+1.74%-11.05%+26.54% 315M
+0.57%-3.12%+17.98%-18.35% 62.21B
+1.44%+5.33%+68.08%+223.49% 59.45B
+0.70%+29.50%+29.50%+29.50% 38.9B
+0.26%+16.11%-55.36%-64.79% 36.4B
+0.15%+2.67%+51.58%-36.01% 29.52B
+1.12%+6.55%+57.59%+75.66% 21.54B
+1.42%+6.16%+84.13%-59.23% 19.7B
+4.80%+0.07%-4.38%+103.05% 16.18B
+0.18%-1.66%+49.80%+101.47% 15.89B
Average +1.08%+1.64%+28.79%+38.13% 30.01B
Weighted average by Cap. +0.97%+2.93%+31.44%+45.39%

Financials

2026 *2027 *
Net sales 65.51M 56.58M 52.14M 48.8M 91.46M 6.23B 92.88M 616M 240M 3.03B 246M 241M 10.49B 135M 117M 107M 101M 188M 12.83B 191M 1.27B 494M 6.24B 506M 496M 21.62B
Net income -42.25M -36.49M -33.63M -31.48M -58.99M -4.02B -59.91M -397M -155M -1.95B -159M -155M -6.77B -2.1M -1.81M -1.67M -1.57M -2.93M -200M -2.98M -19.75M -7.7M -97.21M -7.89M -7.72M -337M
Net Debt - -
Logo Abeona Therapeutics Inc.
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. The Company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa. Its fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. Its development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Its AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Its pipeline programs include ABO-504 (Stargardt disease), ABO-503 (X-linked retinoschisis), ABO-505 (autosomal dominant optic atrophy), UX111 (Sanfilippo Syndrome Type A (MPS IIIA)), TSHA-102 (Rett Syndrome), and TSHA-118 (Infantile Batten Disease (CLN1 Disease)).
Employees
226
Date Price Change Volume
26-06-12 5.530 $ 0.00% 956,347
26-06-11 5.530 $ +3.17% 1,126,241
26-06-10 5.360 $ -1.65% 1,013,145
26-06-09 5.450 $ +1.30% 1,159,615
26-06-08 5.380 $ -1.47% 706,938
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
5.530USD
Average target price
19.71USD
Spread / Average Target
+256.50%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ABEO Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!